RFLRafael Holdings, Inc.
The schedule
- Thu15Oct
Expected management update on the strategic direction, potential M&A pivots, and utilization of RFL's remaining $30.49M cash balance.
- Tue15Dec
Q4 2026 earnings report, focusing heavily on full-year fiscal cash burn and remaining liquidity.
- Tue16Mar
Q1 2027 operational update and financial print, evaluating early 2027 cash burn and real estate service revenues.
- Tue15Jun
Q2 2027 earnings, marking a critical juncture for RFL's listing compliance if the share price has slipped below $1.00.
Past
- Tue16Jun
Actual outcome: Bear · $2.23 at outcome
Rafael Holdings reported Q3 2026 EPS that exactly met estimates at -$0.08 and announced the completion of the last patient visit for its Phase 3 Trappsol Cyclo trial. However, with the stock heavily overbought following a massive runup prior to the event, the in-line financial results and clinical update triggered profit-taking, resulting in a 12.2% decline.
Rafael Holdings reports Q3 2026 earnings amidst heavily overbought technicals (RSI 75.7) and a massive recent runup to $2.16.
- Wed10Jun
Actual outcome: Bull · $2.36 at outcome
RFL announced it has completed the last patient visit for its Phase 3 trial of Trappsol Cyclo and expects to submit an NDA in the second half of 2026. The FDA acknowledged the company's US Expanded Access Program, signaling regulatory momentum and potential approval, which drove a strong risk-adjusted move. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-09-10: +74.2% from 2026-05-01 (~3.1σ). Target date 2026-09-01 reached; move through 2026-09-10 observed.
RFL announced it has completed the last patient visit for its Phase 3 trial of Trappsol Cyclo and expects to submit an NDA in the second half of 2026. The FDA acknowledged the company's US Expanded Access Program, signaling regulatory momentum and potential approval, which drove a strong risk-adjusted move. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-09-10: +74.2% from 2026-05-01 (~3.1σ). Target date 2026-09-01 reached; move through 2026-09-10 observed.
- Thu30Apr
Actual outcome: Bull · $1.39 at outcome
Rafael Holdings reported Q2 FY26 EPS of -$0.13, perfectly matching analyst estimates. The stock's rally was largely driven by a recently announced patent licensing agreement with MIT to develop small molecules for ApoE4-positive Alzheimer's Disease. This strategic expansion of their intellectual property portfolio, combined with a stable cash burn trajectory, provided investors with confidence and pushed shares well past the bull target.
Q2 FY26 results on 2026-04-30 will update Rafael Holdings' cash burn, minimal real estate services revenue trajectory, and any commentary on strategic alternatives, with the stock at $1.21 into the print.
